vida: extract claims from 2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients.md - Domain: health - Claims: 1, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
This commit is contained in:
Teleo Agents
parent
70639727b6
commit
6087355df2
5 changed files with 47 additions and 4 deletions
|
|
@ -11,7 +11,7 @@ sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md
|
|||
scope: causal
|
||||
sourcer: PubMed/ClinicalTrials.gov systematic review
|
||||
challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
|
||||
related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
|
||||
related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
|
||||
supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery"]
|
||||
reweave_edges: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24"]
|
||||
---
|
||||
|
|
@ -67,3 +67,10 @@ NCT06548490 is the first Phase 2 RCT testing semaglutide for treatment-refractor
|
|||
**Source:** Hendershot et al., JAMA Psychiatry 2025
|
||||
|
||||
First RCT evidence: 26-week trial of 108 AUD+obesity patients showed semaglutide+CBT reduced heavy drinking days 41.1%, with NNT 4.3 versus 7+ for approved AUD medications. Blood-alcohol biomarkers corroborated self-reports. However, a separate cohort study found 195% increased MDD risk with GLP-1 agonists, requiring psychiatric screening.
|
||||
|
||||
|
||||
## Supporting Evidence
|
||||
|
||||
**Source:** eClinicalMedicine meta-analysis, December 2025
|
||||
|
||||
Meta-analysis of 5.26M patients across 14 studies confirms 28-36% reduction in AUD-related outcomes with neuroimaging evidence of attenuated alcohol cue reactivity and dopaminergic signaling. Objective biomarkers (PEth, γ-GT) validate self-reported reductions. Effect generalizes beyond treatment-seeking populations to metabolic patients prescribed GLP-1s for T2D/obesity.
|
||||
|
|
|
|||
|
|
@ -12,9 +12,16 @@ scope: causal
|
|||
sourcer: NIH / JAMA Psychiatry
|
||||
supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
|
||||
challenges: ["the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"]
|
||||
related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression"]
|
||||
related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
|
||||
---
|
||||
|
||||
# GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications
|
||||
|
||||
A 26-week randomized, double-blind, placebo-controlled trial of 108 patients with both alcohol use disorder and obesity found that weekly semaglutide plus standard cognitive behavioral therapy produced a 41.1% reduction in heavy drinking days, with 13.7% greater improvement than placebo. The number needed to treat (NNT) was 4.3 — meaning approximately 4-5 patients need treatment to prevent one heavy drinking day. This represents a substantial improvement over approved AUD medications: naltrexone and acamprosate have NNTs of 7 or higher. Blood-alcohol biomarkers corroborated self-reported data, addressing a common validity concern in addiction research. The mechanism is hypothesized to involve GLP-1 receptor modulation of mesolimbic dopamine pathways, reducing the hedonic value of alcohol similar to how it reduces food craving. However, this finding is limited to the studied population: adults with comorbid AUD and obesity, which represents approximately 40% of AUD patients. A separate community-based cohort study found 195% increased risk of major depressive disorder among individuals treated with liraglutide or semaglutide, though this observational finding may be confounded by indication (obese/metabolically ill patients have higher baseline depression rates). Phase 3 trials are now underway to determine whether this efficacy translates to broader AUD populations and whether the depression risk signal is causal.
|
||||
|
||||
|
||||
## Extending Evidence
|
||||
|
||||
**Source:** eClinicalMedicine meta-analysis, December 2025
|
||||
|
||||
Meta-analysis demonstrates AUD reduction effect extends beyond comorbid obesity population. Most evidence comes from metabolic patients (T2D/obesity) prescribed GLP-1s for metabolic indications, not AUD-primary treatment. This suggests the mechanism is not limited to the obesity+AUD comorbidity but operates through reward circuit modulation across populations.
|
||||
|
|
|
|||
|
|
@ -0,0 +1,19 @@
|
|||
---
|
||||
type: claim
|
||||
domain: health
|
||||
description: Population-level validation of GLP-1 AUD efficacy combining RCT evidence with real-world effectiveness data across metabolic patient populations
|
||||
confidence: likely
|
||||
source: eClinicalMedicine (The Lancet), 14-study meta-analysis, December 2025
|
||||
created: 2026-05-03
|
||||
title: GLP-1 receptor agonists reduce alcohol consumption and AUD risk by 28-36 percent across diverse populations as demonstrated by meta-analysis of 5.26 million patients
|
||||
agent: vida
|
||||
sourced_from: health/2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients.md
|
||||
scope: causal
|
||||
sourcer: eClinicalMedicine / The Lancet
|
||||
supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
|
||||
related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
|
||||
---
|
||||
|
||||
# GLP-1 receptor agonists reduce alcohol consumption and AUD risk by 28-36 percent across diverse populations as demonstrated by meta-analysis of 5.26 million patients
|
||||
|
||||
A systematic review and meta-analysis published in eClinicalMedicine synthesized 14 studies (4 RCTs + 10 observational) covering 5,262,268 patients and found consistent reductions in alcohol consumption and AUD-related outcomes. AUDIT scores decreased by mean difference −7.81 points (95% CI −9.02 to −6.60), representing a clinically meaningful reduction. Alcohol-related events (AUD incidence, recurrence, hospitalizations, acute intoxication) showed HR 0.64 (95% CI 0.59–0.69), a 36% reduction. AUD diagnosis risk showed HR 0.72 (95% CI 0.59–0.89), a 28% reduction. Semaglutide and liraglutide showed most consistent effects. Critically, most evidence comes from individuals with T2D or obesity prescribed GLP-1s for metabolic indications, not AUD-primary treatment-seeking patients, suggesting the effect generalizes beyond the SEMALCO population (treatment-seeking AUD+obesity with CBT co-treatment). Objective biomarkers confirmed the effect: PEth (phosphatidylethanol) and γ-GT (gamma-glutamyltransferase) reductions documented. Neuroimaging showed attenuated alcohol cue reactivity and dopaminergic signaling with GLP-1 use, providing mechanistic confirmation that GLP-1 modulates reward salience through VTA dopamine pathways, not just appetite suppression. High heterogeneity (I² = 87.5% for AUDIT) reflects diverse study designs, populations, and GLP-1 drugs, but directional consistency across all 14 studies and 5.26M patients makes this one of the most robust findings in GLP-1 behavioral health evidence. Three independent meta-analyses in 2025-2026 converged on similar effect sizes (28-36% risk reduction), indicating rapid field maturation. This represents the convergence of RCT efficacy (SEMALCO) and real-world effectiveness (this meta-analysis) across different populations—an unusual evidence pattern for a field this new.
|
||||
|
|
@ -11,7 +11,7 @@ sourced_from: health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.m
|
|||
scope: causal
|
||||
sourcer: Hendershot CS et al.
|
||||
supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
|
||||
related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression"]
|
||||
related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
|
||||
---
|
||||
|
||||
# Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
|
||||
|
|
@ -31,3 +31,10 @@ Meta-analysis confirms semaglutide as best-performing agent for alcohol reductio
|
|||
**Source:** Qeadan F et al., Addiction 2025
|
||||
|
||||
Real-world observational data from 817,309 AUD patients (5,621 with GLP-1 RA) shows 50% lower alcohol intoxication rates (IRR 0.50, 95% CI 0.40-0.63) over 24 months, consistent with Hendershot RCT findings. Effect maintained across T2DM (IRR 0.51), obesity (IRR 0.58), and combined conditions (IRR 0.58) subgroups. Provides population-scale corroboration of the VTA dopamine mechanism hypothesis, though observational confounding limits causal inference.
|
||||
|
||||
|
||||
## Supporting Evidence
|
||||
|
||||
**Source:** eClinicalMedicine meta-analysis, December 2025
|
||||
|
||||
Semaglutide showed most consistent AUD reduction effects across 14 studies in meta-analysis. RCT findings documented reduced drinking days, units per drinking day, and cravings particularly with semaglutide. Neuroimaging confirmed attenuated alcohol cue reactivity with GLP-1 use, validating VTA dopamine suppression mechanism.
|
||||
|
|
|
|||
|
|
@ -7,10 +7,13 @@ date: 2025-12-01
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: research-article
|
||||
status: unprocessed
|
||||
status: processed
|
||||
processed_by: vida
|
||||
processed_date: 2026-05-03
|
||||
priority: high
|
||||
tags: [GLP-1, semaglutide, alcohol-use-disorder, meta-analysis, systematic-review, population-level, behavioral-health]
|
||||
intake_tier: research-task
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
Loading…
Reference in a new issue